Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis

Tavs Qvist; Tania Pressler; Niels Høiby; Terese L Katzenstein

doi:10.1186/1465-9921-15-41

Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis

Tavs Qvist, Tania Pressler, Niels Høiby, Terese L Katzenstein

46 Citations (Scopus)

Abstract

Important paradigms of pulmonary disease with nontuberculous mycobacteria (NTM) are currently shifting based on an increasing attention within the field of cystic fibrosis (CF). These shifts are likely to benefit the management of all patients with pulmonary NTM, regardless of underlying pathology. Currently several key areas are being revised: The first outbreak of human NTM transmission has been proven and new evidence of biofilm growth in vivo has been demonstrated. A better understanding of the clinical impact of NTM infection has led to increased diagnostic vigilance and new recommendations for lung transplantation are under way. While recent changes have reinvigorated the interest in NTM disease, the challenge remains, whether such advances can be successfully translated into improved management and care.

Original language	English
Article number	41
Journal	Respiratory research
Volume	15
Pages (from-to)	1-6
Number of pages	6
ISSN	1465-9921
DOIs	https://doi.org/10.1186/1465-9921-15-41
Publication status	Published - 11 Apr 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1465-9921-15-41

Cite this

@article{4aa62615b52a4abc8978f4a393af328a,

title = "Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis",

abstract = "Important paradigms of pulmonary disease with nontuberculous mycobacteria (NTM) are currently shifting based on an increasing attention within the field of cystic fibrosis (CF). These shifts are likely to benefit the management of all patients with pulmonary NTM, regardless of underlying pathology. Currently several key areas are being revised: The first outbreak of human NTM transmission has been proven and new evidence of biofilm growth in vivo has been demonstrated. A better understanding of the clinical impact of NTM infection has led to increased diagnostic vigilance and new recommendations for lung transplantation are under way. While recent changes have reinvigorated the interest in NTM disease, the challenge remains, whether such advances can be successfully translated into improved management and care.",

keywords = "Anti-Bacterial Agents, Biofilms, Cystic Fibrosis, Humans, Mycobacterium Infections, Nontuberculous, Nontuberculous Mycobacteria",

author = "Tavs Qvist and Tania Pressler and Niels H{\o}iby and Katzenstein, {Terese L}",

year = "2014",

month = apr,

day = "11",

doi = "10.1186/1465-9921-15-41",

language = "English",

volume = "15",

pages = "1--6",

journal = "Respiratory Research (Print)",

issn = "1465-9921",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis

AU - Qvist, Tavs

AU - Pressler, Tania

AU - Høiby, Niels

AU - Katzenstein, Terese L

PY - 2014/4/11

Y1 - 2014/4/11

N2 - Important paradigms of pulmonary disease with nontuberculous mycobacteria (NTM) are currently shifting based on an increasing attention within the field of cystic fibrosis (CF). These shifts are likely to benefit the management of all patients with pulmonary NTM, regardless of underlying pathology. Currently several key areas are being revised: The first outbreak of human NTM transmission has been proven and new evidence of biofilm growth in vivo has been demonstrated. A better understanding of the clinical impact of NTM infection has led to increased diagnostic vigilance and new recommendations for lung transplantation are under way. While recent changes have reinvigorated the interest in NTM disease, the challenge remains, whether such advances can be successfully translated into improved management and care.

AB - Important paradigms of pulmonary disease with nontuberculous mycobacteria (NTM) are currently shifting based on an increasing attention within the field of cystic fibrosis (CF). These shifts are likely to benefit the management of all patients with pulmonary NTM, regardless of underlying pathology. Currently several key areas are being revised: The first outbreak of human NTM transmission has been proven and new evidence of biofilm growth in vivo has been demonstrated. A better understanding of the clinical impact of NTM infection has led to increased diagnostic vigilance and new recommendations for lung transplantation are under way. While recent changes have reinvigorated the interest in NTM disease, the challenge remains, whether such advances can be successfully translated into improved management and care.

KW - Anti-Bacterial Agents

KW - Biofilms

KW - Cystic Fibrosis

KW - Humans

KW - Mycobacterium Infections, Nontuberculous

KW - Nontuberculous Mycobacteria

U2 - 10.1186/1465-9921-15-41

DO - 10.1186/1465-9921-15-41

M3 - Comment/debate

C2 - 24725650

SN - 1465-9921

VL - 15

SP - 1

EP - 6

JO - Respiratory Research (Print)

JF - Respiratory Research (Print)

M1 - 41

ER -

Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this